Every pharma company wants to use AI. Most can't.
Innovation teams have budget and mandate but struggle to find use cases they can actually execute. When they do find one, they build custom — expensive, slow, and the compliance team blocks it because nobody knows how to validate AI in a GxP process. Meanwhile, operations still run on spreadsheets and email.
Three things converged that make this the right moment:
-
LLMs matured to cognitive work. Agents can genuinely review documents, extract insights, write drafts, detect patterns. This isn't a chatbot toy — it's a real worker.
-
Pharma must adopt AI but can't "move fast and break things." Efficiency pressure is growing. But regulated environments need structure, auditability, and control that doesn't exist yet.
-
No standard exists. Every company reinvents how to integrate AI into their processes. Whoever establishes "how humans and agents collaborate in regulated processes" first defines the category.
AI in pharma isn't a technology problem — it's an infrastructure problem. The models are ready. What's missing is the methodology, the compliance layer, and proven examples of what good looks like.
Humans stay in control. Agents assist, draft, flag, and execute — but always within boundaries set by the workspace. The system enforces this at the infrastructure level, not as an afterthought.
Compliance shouldn't be a separate project. When you build on Mediforce, audit trails, accountability, and data integrity come with the platform. You don't validate AI compliance separately — it's built in.
Open source is the right model for regulated industries. Closed platforms mean vendor lock-in, opaque decisions, and long procurement cycles. Open source means transparency, trust, and community-driven quality.
Start with working applications, not abstractions. We build concrete apps first, extract shared patterns into the platform as they emerge.
When people hear "AI in pharma," they often picture a chat window in the corner of a screen. That's not what we're talking about.
The agents in Mediforce are as diverse as the work they support. Consider what's possible in just one process like informed consent:
- An agent that reviews consent forms and simplifies language into clear, patient-friendly wording
- An agent that analyzes scanned documents and flags missing signatures or incomplete fields
- An agent that monitors consent metrics and alerts you to anomalies — unusual withdrawal rates at a specific site, slow enrollment in a region
- An agent that handles routine patient outreach — scheduling follow-up calls when patients can't be reached
- An agent that answers patient questions about trial materials and procedures, within boundaries set by the study team
That's five very different types of work — from document analysis to anomaly detection to natural language conversation — in a single process.
And informed consent is just one example. We're exploring agent-powered workflows ranging from drug discovery through clinical studies and reporting, up to operations and getting approved drugs to patients.
Every one of these agents operates under human oversight. You define what it's allowed to do, how it escalates, and how its actions are recorded.
Mediforce aims to become the standard infrastructure for deploying AI agents into regulated business processes. Not a hosted SaaS — an open-source platform you own, deploy, and customize.
The model: 80% ready, 20% yours. You get production-grade process templates out of the box. Deploy them, adapt to your workspace's specific needs and regulations, done. Want to build something entirely new? Use the same platform, the same compliance infrastructure, the same agent runtime.
Each new process is easier than the last. The compliance infrastructure and agent runtime are already in place. The first process is the hardest; each subsequent one is incremental.
A pharma company discovers Mediforce. They deploy their first process application in weeks — not months. Their compliance team validates it quickly because the audit trail, data integrity, and accountability are built into the platform. Their innovation team sees it working and says: "Let's do the same for pharmacovigilance." And they can, because the infrastructure is already there.
That's the future we're building toward. We're not there yet. But we're building in the open, and we'd love your help getting there.